Heron Therapeutics Inc. (HRTX)

18.45
0.15 0.83
NASDAQ : Health Technology
Prev Close 18.60
Open 18.49
Day Low/High 18.29 / 18.87
52 Wk Low/High 15.68 / 31.81
Volume 1.12M
Avg Volume 990.20K
Exchange NASDAQ
Shares Outstanding 88.39M
Market Cap 1.58B
EPS -2.40
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Heron Therapeutics Announces Proposed Public Offering Of Common Stock

Heron Therapeutics Announces Proposed Public Offering Of Common Stock

SAN DIEGO, Oct. 3, 2019 /PRNewswire/ -- Heron Therapeutics, Inc.

Heron Shares Rise on Phase III Results of Agent Used in Knee Replacements

Heron Shares Rise on Phase III Results of Agent Used in Knee Replacements

Study results show 75% of knee-replacement patients were discharged from the hospital without a prescription for opioids.

Heron Announces Positive Topline Results From Phase 3b Clinical Study Of HTX-011 In Total Knee Arthroplasty

Heron Announces Positive Topline Results From Phase 3b Clinical Study Of HTX-011 In Total Knee Arthroplasty

- Mean Pain Scores Remain in Mild Range for 72 Hours following Surgery -

Heron Therapeutics Appoints Kimberly Manhard To Board Of Directors

Heron Therapeutics Appoints Kimberly Manhard To Board Of Directors

SAN DIEGO, Oct. 1, 2019 /PRNewswire/ -- Heron Therapeutics, Inc.

Heron Therapeutics Appoints Stephen Davis To Board Of Directors

Heron Therapeutics Appoints Stephen Davis To Board Of Directors

SAN DIEGO, Oct. 1, 2019 /PRNewswire/ -- Heron Therapeutics, Inc.

Heron Therapeutics Resubmits New Drug Application To FDA For HTX-011 For The Management Of Postoperative Pain

Heron Therapeutics Resubmits New Drug Application To FDA For HTX-011 For The Management Of Postoperative Pain

SAN DIEGO, Oct. 1, 2019 /PRNewswire/ -- Heron Therapeutics, Inc.

November 15th Options Now Available For Heron Therapeutics (HRTX)

November 15th Options Now Available For Heron Therapeutics (HRTX)

Investors in Heron Therapeutics Inc saw new options become available today, for the November 15th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the HRTX options chain for the new November 15th contracts and identified one put and one call contract of particular interest.

Heron Therapeutics To Present At The 2019 Cantor Global Healthcare Conference

Heron Therapeutics To Present At The 2019 Cantor Global Healthcare Conference

SAN DIEGO, Sept. 25, 2019 /PRNewswire/ -- Heron Therapeutics, Inc.

HRTX: Insiders Vs. Shorts

HRTX: Insiders Vs. Shorts

The most recent short interest data was recently released for the 04/15/2019 settlement date, and Heron Therapeutics Inc is one of the most shorted stocks of the Russell 3000, based on 16.55 "days to cover" versus the median component at 5.30. There are a number of ways to look at short data, but one metric that we find particularly useful is the "days to cover" because it considers both the total shares short and the average daily volume of shares typically traded.

Interesting HRTX Put And Call Options For October 18th

Interesting HRTX Put And Call Options For October 18th

Investors in Heron Therapeutics Inc saw new options begin trading this week, for the October 18th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the HRTX options chain for the new October 18th contracts and identified one put and one call contract of particular interest.

Heron Therapeutics Announces Publication Of Results From EPOCH 2, A Phase 3 Study Of HTX-011 In Patients Undergoing Hernia Repair Surgery

Heron Therapeutics Announces Publication Of Results From EPOCH 2, A Phase 3 Study Of HTX-011 In Patients Undergoing Hernia Repair Surgery

SAN DIEGO, Aug. 20, 2019 /PRNewswire/ -- Heron Therapeutics, Inc.

Final Deadline:(HRTX) Heron Therapeutics, Inc. - Bronstein, Gewirtz & Grossman, LLC Reminds Investors Of Class Action And Lead Plaintiff Deadline: August 5, 2019

Final Deadline:(HRTX) Heron Therapeutics, Inc. - Bronstein, Gewirtz & Grossman, LLC Reminds Investors Of Class Action And Lead Plaintiff Deadline: August 5, 2019

NEW YORK, Aug. 5, 2019 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Heron Therapeutics, Inc.

Heron Therapeutics Announces Financial Results For The Three And Six Months Ended June 30, 2019 And Highlights Recent Corporate Updates

Heron Therapeutics Announces Financial Results For The Three And Six Months Ended June 30, 2019 And Highlights Recent Corporate Updates

SAN DIEGO, Aug. 5, 2019 /PRNewswire/ -- Heron Therapeutics, Inc.

Federman & Sherwood Reminds Investors Of Imminent Lead Plaintiff Deadline In Securities Class Action Lawsuit Against Heron Therapeutics, Inc.

Federman & Sherwood Reminds Investors Of Imminent Lead Plaintiff Deadline In Securities Class Action Lawsuit Against Heron Therapeutics, Inc.

On June 3, 2019, a class action lawsuit was filed in the United States District Court for the Southern District of California against Heron Therapeutics, Inc.

LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Heron Therapeutics, Inc. To Contact The Firm

LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Heron Therapeutics, Inc. To Contact The Firm

NEW YORK, July 12, 2019 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Heron Therapeutics, Inc.

UPCOMING DEADLINE ALERT: The Schall Law Firm Announces It Is Investigating Claims Against Heron Therapeutics, Inc. And Encourages Investors With Losses In Excess Of $100,000 To Contact The Firm

UPCOMING DEADLINE ALERT: The Schall Law Firm Announces It Is Investigating Claims Against Heron Therapeutics, Inc. And Encourages Investors With Losses In Excess Of $100,000 To Contact The Firm

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Heron Therapeutics, Inc.

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders With Losses On Their Investment In Heron Therapeutics, Inc. Of Class Action Lawsuit And Upcoming Deadline - HRTX

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders With Losses On Their Investment In Heron Therapeutics, Inc. Of Class Action Lawsuit And Upcoming Deadline - HRTX

NEW YORK, June 17, 2019 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Heron Therapeutics, Inc.

Glancy Prongay & Murray Reminds Investors Of Looming Deadline In The Class Action Lawsuit Against Heron Therapeutics, Inc.

Glancy Prongay & Murray Reminds Investors Of Looming Deadline In The Class Action Lawsuit Against Heron Therapeutics, Inc.

Glancy Prongay & Murray LLP ("GPM") reminds investors of the upcoming  August 5, 2019 deadline to file a lead plaintiff motion in the class action filed on behalf of Heron Therapeutics, Inc.

Deadline Reminder: The Law Offices Of Howard G. Smith Reminds Investors Of Looming Deadline In The Class Action Lawsuit Against Heron Therapeutics, Inc.

Deadline Reminder: The Law Offices Of Howard G. Smith Reminds Investors Of Looming Deadline In The Class Action Lawsuit Against Heron Therapeutics, Inc.

Law Offices of Howard G. Smith reminds investors of the upcoming  August 5, 2019 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased Heron Therapeutics, Inc.

Heron Therapeutics To Present At 2019 JMP Securities Life Sciences Conference

Heron Therapeutics To Present At 2019 JMP Securities Life Sciences Conference

SAN DIEGO, June 13, 2019 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet...

ROSEN, A GLOBALLY RECOGNIZED LAW FIRM, Announces Filing Of Securities Class Action Lawsuit Against Heron Therapeutics, Inc. - HRTX

ROSEN, A GLOBALLY RECOGNIZED LAW FIRM, Announces Filing Of Securities Class Action Lawsuit Against Heron Therapeutics, Inc. - HRTX

NEW YORK, June 12, 2019 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Heron Therapeutics, Inc.

Glancy Prongay & Murray LLP Announces The Filing Of A Securities Class Action On Behalf Of Heron Therapeutics, Inc. Investors

Glancy Prongay & Murray LLP Announces The Filing Of A Securities Class Action On Behalf Of Heron Therapeutics, Inc. Investors

Glancy Prongay & Murray LLP ("GPM"), a national investors rights law firm, announces that a class action lawsuit has been filed on behalf of investors that acquired Heron Therapeutics, Inc.

INVESTOR ALERT: Law Offices Of Howard G. Smith Announces The Filing Of A Securities Class Action On Behalf Of Heron Therapeutics, Inc. Investors (HRTX)

INVESTOR ALERT: Law Offices Of Howard G. Smith Announces The Filing Of A Securities Class Action On Behalf Of Heron Therapeutics, Inc. Investors (HRTX)

Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Heron Therapeutics, Inc.

Federman & Sherwood Announces Filing Of Securities Class Action Lawsuit Against Heron Therapeutics, Inc.

Federman & Sherwood Announces Filing Of Securities Class Action Lawsuit Against Heron Therapeutics, Inc.

Federman & Sherwood announces that on June 3, 2019, a class action lawsuit was filed in the United States District Court for the Southern District of California against Heron Therapeutics, Inc.

IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces The Filing Of A Class Action Lawsuit Against Heron Therapeutics, Inc. And Encourages Investors With Losses In Excess Of $100,000 To Contact The Firm

IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces The Filing Of A Class Action Lawsuit Against Heron Therapeutics, Inc. And Encourages Investors With Losses In Excess Of $100,000 To Contact The Firm

The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Heron Therapeutics, Inc.

HRTX Class Action Alert: Bernstein Liebhard LLP Announces That A Securities Class Action Lawsuit Has Been Filed Against Heron Therapeutics, Inc. -- HRTX

HRTX Class Action Alert: Bernstein Liebhard LLP Announces That A Securities Class Action Lawsuit Has Been Filed Against Heron Therapeutics, Inc. -- HRTX

NEW YORK, June 4, 2019 /PRNewswire/ -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, announced that a securities class action lawsuit has been filed on behalf of those who purchased or acquired the securities of Heron...

EQUITY ALERT: Rosen Law Firm Announces Filing Of Securities Class Action Lawsuit Against Heron Therapeutics, Inc. - HRTX

EQUITY ALERT: Rosen Law Firm Announces Filing Of Securities Class Action Lawsuit Against Heron Therapeutics, Inc. - HRTX

Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Heron Therapeutics, Inc.